{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:45:38Z","timestamp":1790109938485,"version":"4.0.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s11060-023-04382-8","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T04:02:24Z","timestamp":1688702544000},"page":"663-674","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Tumor immune microenvironment in pituitary neuroendocrine tumors (PitNETs): increased M2 macrophage infiltration and PD-L1 expression in PIT1-lineage subset"],"prefix":"10.1007","volume":"163","author":[{"given":"Mei","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,7]]},"reference":[{"key":"4382_CR1","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1001\/jama.2023.5444","volume":"329","author":"NA Tritos","year":"2023","unstructured":"Tritos NA, Miller KK (2023) Diagnosis and management of Pituitary Adenomas: a review. JAMA 329:1386\u20131398. https:\/\/doi.org\/10.1001\/jama.2023.5444","journal-title":"JAMA"},{"key":"4382_CR2","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnac010","author":"S Melmed","year":"2022","unstructured":"Melmed S, Kaiser UB, Lopes MB, Bertherat J, Syro LV, Raverot G, Reincke M, Johannsson G, Beckers A, Fleseriu M, Giustina A, Wass JAH, Ho KKY (2022) Clinical Biology of the Pituitary Adenoma. Endocr Rev. https:\/\/doi.org\/10.1210\/endrev\/bnac010","journal-title":"Endocr Rev"},{"key":"4382_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","volume":"33","author":"SL Asa","year":"2022","unstructured":"Asa SL, Mete O, Perry A, Osamura RY (2022) Overview of the 2022 WHO classification of Pituitary Tumors. Endocr Pathol 33:6\u201326. https:\/\/doi.org\/10.1007\/s12022-022-09703-7","journal-title":"Endocr Pathol"},{"key":"4382_CR4","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad098","author":"P Burman","year":"2023","unstructured":"Burman P, Casar-Borota O, Perez-Rivas LG, Dekkers OM (2023) Aggressive pituitary tumors and pituitary carcinomas: from pathology to treatment. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgad098","journal-title":"J Clin Endocrinol Metab"},{"key":"4382_CR5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.semcancer.2022.08.004","volume":"86","author":"S Yenyuwadee","year":"2022","unstructured":"Yenyuwadee S, Aliazis K, Wang Q, Christofides A, Shah R, Patsoukis N, Boussiotis VA (2022) Immune cellular components and signaling pathways in the tumor microenvironment. Semin Cancer Biol 86:187\u2013201. https:\/\/doi.org\/10.1016\/j.semcancer.2022.08.004","journal-title":"Semin Cancer Biol"},{"key":"4382_CR6","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12957-021-02272-9","volume":"19","author":"D Nie","year":"2021","unstructured":"Nie D, Fang Q, Li B, Cheng J, Li C, Gui S, Zhang Y, Zhao P (2021) Research advances on the immune research and prospect of immunotherapy in pituitary adenomas. World J Surg Oncol 19:162. https:\/\/doi.org\/10.1186\/s12957-021-02272-9","journal-title":"World J Surg Oncol"},{"key":"4382_CR7","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s11102-022-01211-5","volume":"25","author":"P Marques","year":"2022","unstructured":"Marques P, Silva AL, L\u00f3pez-Presa D, Faria C, Bugalho MJ (2022) The microenvironment of pituitary adenomas: biological, clinical and therapeutical implications. Pituitary 25:363\u2013382. https:\/\/doi.org\/10.1007\/s11102-022-01211-5","journal-title":"Pituitary"},{"key":"4382_CR8","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnac024","author":"MD Ilie","year":"2022","unstructured":"Ilie MD, Vasiljevic A, Bertolino P, Raverot G (2022) Biological and therapeutic implications of the Tumor Microenvironment in Pituitary Adenomas. Endocr Rev. https:\/\/doi.org\/10.1210\/endrev\/bnac024","journal-title":"Endocr Rev"},{"key":"4382_CR9","doi-asserted-by":"publisher","first-page":"785050","DOI":"10.3389\/fendo.2021.785050","volume":"12","author":"C Han","year":"2021","unstructured":"Han C, Lin S, Lu X, Xue L, Wu ZB (2021) Tumor-Associated Macrophages: New Horizons for Pituitary Adenoma researches. Front Endocrinol 12:785050. https:\/\/doi.org\/10.3389\/fendo.2021.785050","journal-title":"Front Endocrinol"},{"key":"4382_CR10","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1530\/erc-22-0037","volume":"29","author":"MD Ilie","year":"2022","unstructured":"Ilie MD, Vasiljevic A, Jouanneau E, Raverot G (2022) Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review. Endocrine-related Cancer 29:415\u2013426. https:\/\/doi.org\/10.1530\/erc-22-0037","journal-title":"Endocrine-related Cancer"},{"key":"4382_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00484-3","author":"JJ Wright","year":"2021","unstructured":"Wright JJ, Powers AC, Johnson DB (2021) Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol. https:\/\/doi.org\/10.1038\/s41574-021-00484-3","journal-title":"Nat Rev Endocrinol"},{"key":"4382_CR12","doi-asserted-by":"publisher","unstructured":"Shalit A, Sarantis P, Koustas E, Trifylli EM, Matthaios D, Karamouzis MV (2023) Predictive biomarkers for Immune-Related Endocrinopathies following Immune checkpoint inhibitors treatment. Cancers 15. https:\/\/doi.org\/10.3390\/cancers15020375","DOI":"10.3390\/cancers15020375"},{"key":"4382_CR13","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1530\/eje-22-0647","volume":"187","author":"MD Ilie","year":"2022","unstructured":"Ilie MD, Villa C, Cuny T, Cortet C, Assie G, Baussart B, Cancel M, Chanson P, Decoudier B, Deluche E, Di Stefano AL, Drui D, Gaillard S, Goichot B, Huillard O, Joncour A, Larrieu-Ciron D, Libe R, Nars G, Vasiljevic A, Raverot G (2022) Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study. Eur J Endocrinol 187:685\u2013696. https:\/\/doi.org\/10.1530\/eje-22-0647","journal-title":"Eur J Endocrinol"},{"key":"4382_CR14","doi-asserted-by":"publisher","DOI":"10.3171\/2014.12.Jns141083","author":"AS Micko","year":"2015","unstructured":"Micko AS, W\u00f6hrer A, Wolfsberger S, Knosp E (2015) Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification. J Neurosurg. https:\/\/doi.org\/10.3171\/2014.12.Jns141083. 122 803 \u2013 11","journal-title":"J Neurosurg"},{"key":"4382_CR15","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA (2015) Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 12:453\u2013457. https:\/\/doi.org\/10.1038\/nmeth.3337","journal-title":"Nat Methods"},{"key":"4382_CR16","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1038\/s41590-022-01267-2","volume":"23","author":"A Christofides","year":"2022","unstructured":"Christofides A, Strauss L, Yeo A, Cao C, Charest A, Boussiotis VA (2022) The complex role of tumor-infiltrating macrophages. Nat Immunol 23:1148\u20131156. https:\/\/doi.org\/10.1038\/s41590-022-01267-2","journal-title":"Nat Immunol"},{"key":"4382_CR17","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s40618-023-02089-1","volume":"46","author":"P Marques","year":"2023","unstructured":"Marques P, Korbonits M (2023) Tumour microenvironment and pituitary tumour behaviour. J Endocrinol Investig 46:1047\u20131063. https:\/\/doi.org\/10.1007\/s40618-023-02089-1","journal-title":"J Endocrinol Investig"},{"key":"4382_CR18","doi-asserted-by":"publisher","unstructured":"Mei Y, Bi WL, Agolia J, Hu C, Giantini Larsen AM, Meredith DM, Al Abdulmohsen S, Bale T, Dunn GP, Abedalthagafi M, Dunn IF (2021) Immune profiling of pituitary tumors reveals variations in immune infiltration and checkpoint molecule expression. https:\/\/doi.org\/10.1007\/s11102-020-01114-3. Pituitary","DOI":"10.1007\/s11102-020-01114-3"},{"key":"4382_CR19","doi-asserted-by":"publisher","unstructured":"Marques P, Barry S, Carlsen E, Collier D, Ronaldson A, Awad S, Dorward N, Grieve J, Mendoza N, Muquit S, Grossman AB, Balkwill F, Korbonits M (2019) Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours. Acta Neuropathol Commun 7172. https:\/\/doi.org\/10.1186\/s40478-019-0830-3","DOI":"10.1186\/s40478-019-0830-3"},{"key":"4382_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10014-018-0314-3","volume":"35","author":"N Inoshita","year":"2018","unstructured":"Inoshita N, Nishioka H (2018) The 2017 WHO classification of pituitary adenoma: overview and comments. Brain Tumor Pathol 35:51\u201356. https:\/\/doi.org\/10.1007\/s10014-018-0314-3","journal-title":"Brain Tumor Pathol"},{"key":"4382_CR21","doi-asserted-by":"publisher","unstructured":"Lu JQ, Adam B, Jack AS, Lam A, Broad RW, Chik CL (2015) Immune Cell infiltrates in Pituitary Adenomas: more macrophages in larger adenomas and more T cells in growth hormone adenomas. Endocrine pathology 26 263 \u2013 72 https:\/\/doi.org\/10.1007\/s12022-015-9383-6","DOI":"10.1007\/s12022-015-9383-6"},{"key":"4382_CR22","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s12020-020-02478-z","volume":"70","author":"P Marques","year":"2020","unstructured":"Marques P, Barry S, Carlsen E, Collier D, Ronaldson A, Dorward N, Grieve J, Mendoza N, Nair R, Muquit S, Grossman AB, Korbonits M (2020) The role of the tumour microenvironment in the angiogenesis of pituitary tumours. Endocrine 70:593\u2013606. https:\/\/doi.org\/10.1007\/s12020-020-02478-z","journal-title":"Endocrine"},{"key":"4382_CR23","doi-asserted-by":"publisher","unstructured":"Principe M, Chanal M, Ilie MD, Ziverec A, Vasiljevic A, Jouanneau E, Hennino A, Raverot G, Bertolino P (2020) Immune Landscape of Pituitary Tumors reveals Association between Macrophages and Gonadotroph Tumor Invasion. J Clin Endocrinol Metab 105. https:\/\/doi.org\/10.1210\/clinem\/dgaa520","DOI":"10.1210\/clinem\/dgaa520"},{"key":"4382_CR24","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.7150\/thno.53749","volume":"11","author":"A Zhang","year":"2021","unstructured":"Zhang A, Xu Y, Xu H, Ren J, Meng T, Ni Y, Zhu Q, Zhang WB, Pan YB, Jin J, Bi Y, Wu ZB, Lin S, Lou M (2021) Lactate-induced M2 polarization of tumor-associated macrophages promotes the invasion of pituitary adenoma by secreting CCL17. Theranostics 11:3839\u20133852. https:\/\/doi.org\/10.7150\/thno.53749","journal-title":"Theranostics"},{"key":"4382_CR25","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.18632\/oncotarget.26775","volume":"10","author":"G Yagnik","year":"2019","unstructured":"Yagnik G, Rutowski MJ, Shah SS, Aghi MK (2019) Stratifying nonfunctional pituitary adenomas into two groups distinguished by macrophage subtypes. Oncotarget 10:2212\u20132223. https:\/\/doi.org\/10.18632\/oncotarget.26775","journal-title":"Oncotarget"},{"key":"4382_CR26","doi-asserted-by":"publisher","unstructured":"Sato M, Tamura R, Tamura H, Mase T, Kosugi K, Morimoto Y, Yoshida K, Toda M (2019) Analysis of Tumor Angiogenesis and Immune Microenvironment in non-functional pituitary endocrine tumors. J Clin Med 8. https:\/\/doi.org\/10.3390\/jcm8050695","DOI":"10.3390\/jcm8050695"},{"key":"4382_CR27","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s11060-020-03476-x","volume":"147","author":"JT Yeung","year":"2020","unstructured":"Yeung JT, Vesely MD, Miyagishima DF (2020) In silico analysis of the immunological landscape of pituitary adenomas. J Neurooncol 147:595\u2013598. https:\/\/doi.org\/10.1007\/s11060-020-03476-x","journal-title":"J Neurooncol"},{"key":"4382_CR28","doi-asserted-by":"publisher","unstructured":"Lin K, Zhang J, Lin Y, Pei Z, Wang S (2022) Metabolic characteristics and M2 macrophage infiltrates in Invasive Nonfunctioning Pituitary Adenomas. Front Endocrinol 13901884. https:\/\/doi.org\/10.3389\/fendo.2022.901884","DOI":"10.3389\/fendo.2022.901884"},{"key":"4382_CR29","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/1348-0421.13041","volume":"67","author":"H Matsuzaki","year":"2023","unstructured":"Matsuzaki H, Komohara Y, Yano H, Fujiwara Y, Kai K, Yamada R, Yoshii D, Uekawa K, Shinojima N, Mikami Y, Mukasa A (2023) Macrophage colony-stimulating factor potentially induces recruitment and maturation of macrophages in recurrent pituitary neuroendocrine tumors. Microbiol Immunol 67:90\u201398. https:\/\/doi.org\/10.1111\/1348-0421.13041","journal-title":"Microbiol Immunol"},{"key":"4382_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-02126-5","author":"L Lyu","year":"2023","unstructured":"Lyu L, Jiang Y, Ma W, Li H, Liu X, Li L, Shen A, Yu Y, Jiang S, Li H, Zhou P, Yin S (2023) Single-cell sequencing of PIT1-positive pituitary adenoma highlights the pro-tumour microenvironment mediated by IFN-\u03b3-induced tumour-associated fibroblasts remodelling. Br J Cancer. https:\/\/doi.org\/10.1038\/s41416-022-02126-5","journal-title":"Br J Cancer"},{"key":"4382_CR31","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41419-021-03703-x","volume":"12","author":"C Tang","year":"2021","unstructured":"Tang C, Lei X, Xiong L, Hu Z, Tang B (2021) HMGA1B\/2 transcriptionally activated-POU1F1 facilitates gastric carcinoma metastasis via CXCL12\/CXCR4 axis-mediated macrophage polarization. Cell Death Dis 12:422. https:\/\/doi.org\/10.1038\/s41419-021-03703-x","journal-title":"Cell Death Dis"},{"key":"4382_CR32","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1038\/s41388-017-0036-8","volume":"37","author":"A Martinez-Ordo\u00f1ez","year":"2018","unstructured":"Martinez-Ordo\u00f1ez A, Seoane S, Cabezas P, Eiro N, Sendon-Lago J, Macia M, Garcia-Caballero T, Gonzalez LO, Sanchez L, Vizoso F, Perez-Fernandez R (2018) Breast cancer metastasis to liver and lung is facilitated by pit-1-CXCL12-CXCR4 axis. Oncogene 37:1430\u20131444. https:\/\/doi.org\/10.1038\/s41388-017-0036-8","journal-title":"Oncogene"},{"key":"4382_CR33","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1038\/s41388-021-01740-6","volume":"40","author":"A Mart\u00ednez-Ordo\u00f1ez","year":"2021","unstructured":"Mart\u00ednez-Ordo\u00f1ez A, Seoane S, Avila L, Eiro N, Mac\u00eda M, Arias E, Pereira F, Garc\u00eda-Caballero T, G\u00f3mez-Lado N, Aguiar P, Vizoso F, Perez-Fernandez R (2021) POU1F1 transcription factor induces metabolic reprogramming and breast cancer progression via LDHA regulation. Oncogene 40:2725\u20132740. https:\/\/doi.org\/10.1038\/s41388-021-01740-6","journal-title":"Oncogene"},{"key":"4382_CR34","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","volume":"48","author":"C Sun","year":"2018","unstructured":"Sun C, Mezzadra R, Schumacher TN (2018) Regulation and function of the PD-L1 checkpoint. Immunity 48:434\u2013452. https:\/\/doi.org\/10.1016\/j.immuni.2018.03.014","journal-title":"Immunity"},{"key":"4382_CR35","doi-asserted-by":"publisher","first-page":"e9056","DOI":"10.1097\/md.0000000000009056","volume":"96","author":"P Wang","year":"2017","unstructured":"Wang P, Wang T, Yang Y, Yu C, Liu N, Yan C (2017) Detection of programmed death ligand 1 protein and CD8 + lymphocyte infiltration in plurihormonal pituitary adenomas: a case report and review of the literatures. Medicine 96:e9056. https:\/\/doi.org\/10.1097\/md.0000000000009056","journal-title":"Medicine"},{"key":"4382_CR36","doi-asserted-by":"publisher","first-page":"4126","DOI":"10.1158\/1078-0432.Ccr-17-2206","volume":"24","author":"MP Salomon","year":"2018","unstructured":"Salomon MP, Wang X, Marzese DM, Hsu SC, Nelson N, Zhang X, Matsuba C, Takasumi Y, Ballesteros-Merino C, Fox BA, Barkhoudarian G, Kelly DF, Hoon DSB (2018) The Epigenomic Landscape of Pituitary Adenomas reveals specific alterations and differentiates among Acromegaly, Cushing\u2019s Disease and endocrine-inactive subtypes. Clin cancer research: official J Am Association Cancer Res 24:4126\u20134136. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-2206","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"key":"4382_CR37","doi-asserted-by":"publisher","first-page":"76565","DOI":"10.18632\/oncotarget.12088","volume":"7","author":"Y Mei","year":"2016","unstructured":"Mei Y, Bi WL, Greenwald NF, Du Z, Agar NY, Kaiser UB, Woodmansee WW, Reardon DA, Freeman GJ, Fecci PE, Laws ER Jr, Santagata S, Dunn GP, Dunn IF (2016) Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. Oncotarget 7:76565\u201376576. https:\/\/doi.org\/10.18632\/oncotarget.12088","journal-title":"Oncotarget"},{"key":"4382_CR38","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11060-018-2844-2","volume":"139","author":"PF Wang","year":"2018","unstructured":"Wang PF, Wang TJ, Yang YK, Yao K, Li Z, Li YM, Yan CX (2018) The expression profile of PD-L1 and CD8(+) lymphocyte in pituitary adenomas indicating for immunotherapy. J Neurooncol 139:89\u201395. https:\/\/doi.org\/10.1007\/s11060-018-2844-2","journal-title":"J Neurooncol"},{"key":"4382_CR39","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s12022-021-09673-2","volume":"32","author":"J Turchini","year":"2021","unstructured":"Turchini J, Sioson L, Clarkson A, Sheen A, Gill AJ (2021) PD-L1 is preferentially expressed in PIT-1 positive pituitary neuroendocrine tumours. Endocr Pathol 32:408\u2013414. https:\/\/doi.org\/10.1007\/s12022-021-09673-2","journal-title":"Endocr Pathol"},{"key":"4382_CR40","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/s41573-021-00155-y","volume":"20","author":"SP Kubli","year":"2021","unstructured":"Kubli SP, Berger T, Araujo DV, Siu LL, Mak TW (2021) Beyond immune checkpoint blockade: emerging immunological strategies. Nat Rev Drug Discov 20:899\u2013919. https:\/\/doi.org\/10.1038\/s41573-021-00155-y","journal-title":"Nat Rev Drug Discov"},{"key":"4382_CR41","doi-asserted-by":"publisher","first-page":"71","DOI":"10.23736\/s0390-5616.18.04419-3","volume":"64","author":"T Maghathe","year":"2020","unstructured":"Maghathe T, Miller WK, Mugge L, Mansour TR, Schroeder J (2020) Immunotherapy and potential molecular targets for the treatment of pituitary adenomas resistant to standard therapy: a critical review of potential therapeutic targets and current developments. J Neurosurg Sci 64:71\u201383. https:\/\/doi.org\/10.23736\/s0390-5616.18.04419-3","journal-title":"J Neurosurg Sci"},{"key":"4382_CR42","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12943-018-0864-3","volume":"17","author":"M Yi","year":"2018","unstructured":"Yi M, Jiao D, Xu H, Liu Q, Zhao W, Han X, Wu K (2018) Biomarkers for predicting efficacy of PD-1\/PD-L1 inhibitors. Mol Cancer 17:129. https:\/\/doi.org\/10.1186\/s12943-018-0864-3","journal-title":"Mol Cancer"},{"key":"4382_CR43","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1158\/1078-0432.Ccr-18-3486","volume":"26","author":"HR Kemeny","year":"2020","unstructured":"Kemeny HR, Elsamadicy AA, Farber SH, Champion CD, Lorrey SJ, Chongsathidkiet P, Woroniecka KI, Cui X, Shen SH, Rhodin KE, Tsvankin V, Everitt J, Sanchez-Perez L, Healy P, McLendon RE, Codd PJ, Dunn IF, Fecci PE (2020) Targeting PD-L1 initiates effective Antitumor immunity in a murine model of Cushing Disease. Clin cancer research: official J Am Association Cancer Res 26:1141\u20131151. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-3486","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"key":"4382_CR44","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.semcancer.2021.03.036","volume":"79","author":"B Shum","year":"2022","unstructured":"Shum B, Larkin J, Turajlic S (2022) Predictive biomarkers for response to immune checkpoint inhibition. Semin Cancer Biol 79:4\u201317. https:\/\/doi.org\/10.1016\/j.semcancer.2021.03.036","journal-title":"Semin Cancer Biol"},{"key":"4382_CR45","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1007\/s00262-020-02611-x","volume":"69","author":"V Suteau","year":"2020","unstructured":"Suteau V, Collin A, Menei P, Rodien P, Rousselet MC, Briet C (2020) Expression of programmed death-ligand 1 (PD-L1) in human pituitary neuroendocrine tumor. Cancer Immunol immunotherapy: CII 69:2053\u20132061. https:\/\/doi.org\/10.1007\/s00262-020-02611-x","journal-title":"Cancer Immunol immunotherapy: CII"},{"key":"4382_CR46","doi-asserted-by":"publisher","unstructured":"[Consensus on the immunohistochemical tests of PD-L1 in solid tumors (2021 version)]. Zhonghua Bing Li Xue Za Zhi 50 710\u2013718. https:\/\/doi.org\/10.3760\/cma.j.cn112151-20210228-00172","DOI":"10.3760\/cma.j.cn112151-20210228-00172"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-023-04382-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-023-04382-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-023-04382-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T10:09:03Z","timestamp":1690884543000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-023-04382-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["4382"],"URL":"https:\/\/doi.org\/10.1007\/s11060-023-04382-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3001593\/v1","asserted-by":"object"}]},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"30 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Research involving human participants, their data or biological materials were reviewed and approved by Medical Ethics Committee of the First Affiliated Hospital of Sun Yat-sen University (protocol number [2022] 229-1).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participant"}}]}}